Q0 and Q1 modifiers in medical billing: Medicare guidelines and usage

Q0 and Q1 modifiers are used on Medicare claims to distinguish investigational clinical services from routine care furnished as part of an approved clinical research study. A billing team should classify the service first, then apply the modifier and confirm that the claim includes the required clinical-trial information.

That distinction matters because Q0 and Q1 describe different roles within the study. The modifier should match the service on the claim line, not simply the fact that the patient is enrolled in research.

What is the Q0 modifier?

CMS defines the Q0 modifier as an investigational clinical service provided in an approved clinical research study. Q0 identifies an item or service that is being investigated as an objective of the study. The investigational service may be approved or unapproved and may or may not otherwise be covered by Medicare.

Q0 does not guarantee payment. Coverage still depends on the applicable Medicare benefit, coverage policy, study requirements, and any device-specific rules. For example, the current Medicare Claims Processing Manual instructs providers to append Q0 to a Category B Investigational Device Exemption code and report the IDE number on the claim.

What is the Q1 modifier?

The Q1 modifier identifies a routine clinical service provided in an approved clinical research study. CMS describes routine services as items and services that are otherwise covered for Medicare beneficiaries, are used in direct patient management, and are not the investigational service itself.

Q1 modifier Medicare billing can include ordinary patient care, services needed to safely provide the investigational item, clinically appropriate monitoring, and reasonable and necessary treatment of study-related complications. Q1 should not be used for a service performed only to collect research data when that service is not used in the patient’s clinical management.

Q0 versus Q1: the practical difference

The simplest way to separate the Q0 and Q1 modifiers is to ask what role the service plays in the study. If the line represents the investigational item or service being studied, Q0 is generally the relevant clinical trial modifier. If the line represents covered routine patient care associated with the study, Q1 is generally the relevant modifier.

A protocol may therefore contain both types of lines. An investigational therapy can be reported differently from clinically appropriate laboratory monitoring or treatment of a complication. The protocol, coverage policy, and medical record should support the classification for each billed service.

What Medicare covers as routine clinical trial costs

Medicare’s National Coverage Determination for routine costs in clinical trials covers routine costs of qualifying clinical trials and reasonable and necessary care used to diagnose or treat complications arising from participation. Routine clinical trial costs can include conventional care, services required to provide the investigational item, appropriate monitoring, prevention of complications, and treatment of complications.

The policy also identifies exclusions. The investigational item itself is generally excluded unless otherwise covered outside the trial. Services performed solely for data collection and not for direct clinical management are excluded, as are items or services the research sponsor customarily provides free of charge. The presence of a study therefore does not make every service payable.

Medicare clinical trial claim requirements

For professional Medicare clinical trial claims, CMS requires the 8-digit clinical trial number for items or services furnished in clinical trials, studies, registries, or Coverage with Evidence Development. On an electronic 837P claim, the number is reported in Loop 2300 REF02 with REF01=P4. On a paper CMS-1500, it is reported in Field 19 with the “CT” prefix.

Professional claims should also include ICD-10-CM diagnosis code Z00.6 in either the primary or secondary position and Q0 or Q1 as appropriate. For routine costs submitted by practitioners and suppliers, current CMS instructions specifically identify Q1 with Z00.6.

Outpatient institutional clinical trial claims require condition code 30, diagnosis code Z00.6, the 8-digit clinical trial identifier, and Q0 on investigational lines or Q1 on routine-service lines. For paper CMS-1450 claims, the trial number is reported with value code D4. Inpatient clinical trial claims are different: CMS states that Q0 and Q1 do not apply because HCPCS codes are not reported on inpatient claims.

Common Q0 and Q1 modifier billing errors

Most problems come from classifying the service incorrectly or omitting another required claim element. Common review points include:

• Using Q0 for routine care or Q1 for the investigational service without checking the study protocol and Medicare coverage rules.
• Submitting Q1 for research-only data collection that is not used in direct patient management.
• Omitting Z00.6, the national clinical trial number, or condition code 30 when the claim type requires it.
• Leaving required IDE information off a Category B investigational device claim.
• Assuming the modifier itself establishes Medicare coverage without checking the applicable policy.

These errors can produce returned claims, unprocessable lines, denials, or payment that does not match the service furnished. A clean claim needs the modifier, diagnosis, trial identifier, claim-type requirements, and documentation to tell the same story.

A practical review before claim submission

Before billing, confirm that the study qualifies for the Medicare coverage pathway being used and separate investigational services from routine care. Then compare the research protocol with the encounter documentation and claim lines rather than assigning modifiers from a generic study-level rule.

Next, validate Z00.6, the national clinical trial number, condition code 30 when applicable, and any IDE information required for the service. The team should be able to explain why each Q0 or Q1 line was classified that way and identify the documentation that supports the decision.

How RCMGen approaches modifier-driven Medicare billing

At RCMGen, modifier review sits inside the broader claim-to-cash workflow rather than being treated as a code-entry task. Our medical billing services connect coding, claim scrubbing, submission, rejection handling, denial management, payment posting, and A/R follow-up so modifier issues can be traced through the full claim lifecycle.

For professional claims, our physician and clinic revenue cycle services focus on accurate claim construction and payer requirements. For institutional workflows, our hospital revenue cycle management services coordinate coding and billing controls across outpatient and inpatient claim types. For Q0 and Q1, the core principle is to identify the service correctly, confirm the study context, include the required Medicare data, and avoid using a modifier as a substitute for documentation.

Frequently asked questions about Q0 and Q1 modifiers